BioSpace News Archive

Terminated its October 2017 agreement for an investment bank to sell up to $25 million in shares of its common stock in an “at-the-market” equity program.

Patients with metastatic uveal melanoma (mUM) treated with IMCgp100 continued to experience a durable tumour response with a median follow up of 19.1 months, without yet reaching median overall survival (OS), according to new Phase I research to be presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting

Kite, a Gilead Company (Nasdaq: GILD), announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV.

Kite, a Gilead Company announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Seasoned leader brings a wealth of experience in commercial and business development

The University of Mount Union is proud to announce it is adding a second degree accelerated Bachelor of Science in Nursing (BSN) program to its successful Department of Nursing.

RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab.

Positive Results Support Development Pathway of AL101 as a Targeted Therapy for Patients with Tumors That Have Activating Notch Mutations

The St. James announced today that Robert Kram, most recently director of programming and content for The St. James, has been named general manager of the 450,000-square foot sports, wellness and active entertainment destination in Fairfax County.

This new and effective methodology will provide a more efficient method to combat one of the most aggressive forms of breast cancer.